An experimental Novartis cancer therapy acquired as part of a $2.1 billion deal now has data from an important study showing it can help patients diagnosed with some of the most difficult cases of prostate cancer live longer. can help.
step 3 . According to learning outcome Released Thursday, treatment with Novartis Therapy 177LU-PSMA-617, in addition to standard of care, showed a statistically significant improvement in overall survival compared to standard of care alone. In addition, the reduction in risk of death was an estimated 38% in the 177LU-PSMA-617 arm compared to those given the standard of care. Novartis is scheduled to present the results of the study on June 6 during the annual meeting of the American Society of Clinical Oncology.
177LU-PSMA-617 is a type of targeted radiation therapy intended for the treatment of advanced cases of prostate cancer. This therapy consists of a radioactive particle attached to a ligand that binds to receptors on the surface of cancer cells. Novartis adds 177LU-PSMA-617 to its pipeline through 2018 acquisition of Endocyte.
Flowing into the blood, the Novartis radioligand is designed to bind to prostate cancer cells that express PSMA, a protein found on castration-resistant prostate cancer cells. This targeted approach is to protect healthy tissue from the effects of radiation. The effect of radiation is also limited to a small area, which in turn limits damage to surrounding cells.
Michael Morris, a medical oncologist at Memorial Sloan Kettering Cancer Center and chair of the study’s scientific committee, said, “Patients with metastatic CRPC (castration-resistant prostate cancer) who have progressed through contemporary hormonal treatments and chemotherapy have more There are few worthwhile therapeutic options.” in a prepared statement. “The study demonstrated that 177Lu-PSMA-617 improves disease progression and prolongs survival, which are key measures of clinical benefit in the mCRPC population.”
The company reported that the median survival for patients treated with Novartis radioligand was 15.3 months, compared to 11.3 months for patients who received the best standard of care. In progressive free survival, which is a measure of how long a patient lives without worsening of the cancer, the median time in the radioligand arm was 8.7 months, compared to 3.4 months in those treated with the standard of care.
Treatment-related Grade 3 or adverse events occurred in 28.4% of patients who received Novartis therapy, compared to 3.9% in the standard of care arm. The most common of these events included anemia, low blood platelets, low levels of lymphocytes, fatigue, urinary tract infections and low levels of a white blood cell called neutrophil. In the group given Novartis therapy and standard of care, 11.9% of participants discontinued treatment due to adverse events. In the standard of care arm, 8.5% of participants discontinued treatment.
Novartis is planning two more studies of its radioligand therapy as an initial line of treatment for patients with prostate cancer. One study will assess the potential use of the therapy in metastatic castration-resistant prostate cancer prior to treatment with taxane, a class of chemotherapy. Another study will test the radioligand in patients whose prostate cancer has spread but may still be treated with hormone therapy.
Novartis isn’t stopping at prostate cancer. The company said it is also exploring the applications of radioligand therapy for other types of tumors.
Public domain image by National Cancer Institute